Ikram, H; Low, CJ; Crozier, IG; Shirlaw, T (February 1992). “Hemodynamic effects of nitroprusside on valvular aortic stenosis”. The American Journal of Cardiology69 (4): 361–366. doi:10.1016/0002-9149(92)90234-P. PMID1734649.
Ozsoylu, S; Coşkun, T (January 1984). “Sodium nitroprusside treatment in erythromelalgia”. European Journal of Pediatrics141 (3): 185–187. doi:10.1007/bf00443224. PMID6698066.
Sirinek, KR; Adcock, DK; Levine, BA (January 1989). “Simultaneous infusion of nitroglycerin and nitroprusside to offset adverse effects of vasopressin during portosystemic shunting”. American Journal of Surgery157 (1): 33–37. doi:10.1016/0002-9610(89)90416-9. PMID2491934.
Katlic, MR; Ramos, LG; Zinner, MJ (August 1978). “Sodium nitroprusside in the treatment of extreme pyrexia (letter)”. The New England Journal of Medicine299 (3): 154. doi:10.1056/nejm197807202990319.
Taradash, MR; Jacobson, LB (September 1975). “Vasodilator therapy of idiopathic lactic acidosis”. The New England Journal of Medicine293 (10): 468–471. doi:10.1056/NEJM197509042931002. PMID239336.
Yusuf, S; Collins, R; MacMahon, S; Peto, R (May 1988). “Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials”. Lancet1 (8594): 1088–92. doi:10.1016/S0140-6736(88)91906-X. PMID2896919.
Blue, MG; Schneider, SM; Noro, S; Fraley, DS (January 1986). “Successful treatment of neuroleptic malignant syndrome with sodium nitroprusside”. Annals of Internal Medicine104 (1): 56–57. doi:10.7326/0003-4819-104-1-56. PMID3940506.
Costard-Jäckle, A; Fowler, MB (January 1992). “Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group”. Journal of the American College of Cardiology19 (1): 48–54. doi:10.1016/0735-1097(92)90050-W. PMID1729345.
Freitas, AF Jr; Bacal, F; Oliveira Júnior Jde, L; Fiorelli, AI; Santos, RH; Moreira, LF; Silva, CP; Mangini, S; Tsutsui, JM; Bocchi, EA (September 2012). “Sildenafil vs. sodium before nitroprusside for the pulmonary hypertension reversibility test before cardiac transplantation”. Arquivos Brasileiros de Cardiologia99 (3): 848–56. doi:10.1590/S0066-782X2012005000076. PMID22898992.
Palhares, DB; Figueiredo, CS; Moura, AJ (January 1998). “Endotracheal inhalatory sodium nitroprusside in severely hypoxic newborns”. Journal of Perinatal Medicine26 (3): 219–224. doi:10.1515/jpme.1998.26.3.219. PMID9773383.
Benitz, WE; Malachowski, N; Cohen, RS; Stevenson, DK; Ariagno, RL; Sunshine, P (January 1985). “Use of sodium nitroprusside in neonates: efficacy and safety”. The Journal of Pediatrics106 (1): 102–110. doi:10.1016/S0022-3476(85)80477-7. PMID3917495.
Levy, WJ; Bay, JW; Sawhny, B; Tank, T (May 1982). “Aminophylline plus nitroprusside and dopamine for treatment of cerebral vasospasm”. Journal of Neurosurgery56 (5): 646–649. doi:10.3171/jns.1982.56.5.0646. PMID7069476.
Thomas, JE; Rosenwasser, RH (January 1999). “Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: initial observations regarding the use of intraventricular sodium nitroprusside in humans”. Neurosurgery44 (1): 48–57. doi:10.1097/00006123-199901000-00026. PMID9894963.
Dierckx, RA; Peters, O; Ebinger, G; Six, R; Corne, L (February 1986). “Intraarterial sodium nitroprusside infusion in the treatment of severe ergotism”. Clinical Neuropharmacology9 (6): 542–548. doi:10.1097/00002826-198612000-00005. PMID3802106.
Carliner, N; Denune, DP; Finch, CS Jr; Goldberg, LI (January 1974). “Sodium nitroprusside treatment of ergotamine-induced peripheral ischemia”. Journal of the American Medical Association227 (3): 308–309. doi:10.1001/jama.1974.03230160036008. PMID4859658.
Kunathai, S; Ayuthya, PS (Winter 1989). “Hemodynamic effects of sodium nitroprusside in infants and children with large ventricular septal defect”. Pediatric Cardiology10 (1): 59. doi:10.1007/bf02328639. PMID2704657.
Bernstein, HG; Bogerts, B; Keilhoff, G (Oct 2005). “The many faces of nitric oxide in schizophrenia. A review”. Schizophrenia Research78 (1): 69–86. doi:10.1016/j.schres.2005.05.019. PMID16005189.
Silberberg, G; Ben-Shachar, D; Navon, R (October 2010). “Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder”. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics153B (7): 1318–1328. doi:10.1002/ajmg.b.31112. PMID20645313.
Bernstein, HG; Keilhoff, G; Steiner, J; Dobrowolny, H; Bogerts, B (November 2011). “Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy”. CNS & Neurological Disorders - Drug Targets10 (7): 792–807. doi:10.2174/187152711798072392. PMID21999729.
Yanik, M; Vural, H; Tutkun, H; Zoroğlu, SS; Savaş, HA; Herken, H; Koçyiğit, A; Keleş, H; Akyol, O (February 2004). “The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder”. European Archives of Psychiatry and Clinical Neuroscience254 (1): 43–47. doi:10.1007/s00406-004-0453-x. PMID14991378.
Fontoura, PC; Pinto, VL; Matsuura, C; Resende Ade, C; de Bem, GF; Ferraz, MR; Cheniaux, E; Brunini, TM; Mendes-Ribeiro, AC (October 2012). “Defective Nitric Oxide–Cyclic Guanosine Monophosphate Signaling in Patients With Bipolar Disorder: A Potential Role for Platelet Dysfunction”. Psychosomatic Medicine74 (8): 873–877. doi:10.1097/PSY.0b013e3182689460. PMID23023680.
Bielau, H; Brisch, R; Bernard-Mittelstaedt, J; Dobrowolny, H; Gos, T; Baumann, B; Mawrin, C; Bernstein, HG; Bogerts, B; Steiner, J (June 2012). “Immunohistochemical evidence for impaired nitric oxide signaling of the locus coeruleus in bipolar disorder”. Brain Research1459: 91–99. doi:10.1016/j.brainres.2012.04.022. PMID22560594.
Gałecki, P; Maes, M; Florkowski, A; Lewiński, A; Gałecka, E; Bieńkiewicz, M; Szemraj, J (March 2011). “Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder”. Journal of Affective Disorders129 (1-3): 175–82. doi:10.1016/j.jad.2010.09.005. PMID20888049.
A. Navaza; G. Chevrier; P. M. Alzari; P. J. Aymonino (1989). “Single-crystal neutron diffraction structure of sodium pentacyanonitrosylferrate(2-) (sodium nitroprusside) dihydrate”. Acta Crystallogr. C45: 839–841. doi:10.1107/S0108270188013691.
Jadwiga Tritt-Goc; Narcyz Piślewski; Stanisław K. Hoffmann (1997). “EPR evidence of the paramagnetism of a long-living metastable excited state of a sodium nitroprusside single crystal”. Chemical Physics Letters268 (5–6): 471–474. Bibcode: 1997CPL...268..471T. doi:10.1016/S0009-2614(97)00217-0.
Coppens, P.; Novozhilova, I.; Kovalevsky, A. (2002). “Photoinduced Linkage Isomers of Transition-Metal Nitrosyl Compounds and Related Complexes”. Chem. Rev.102 (4): 861–883. doi:10.1021/cr000031c.
Hans Reihlen, Adolf v. Friedolsheim (1927). “Über komplexe Stickoxydverbindungen und das sogenannte einwertige Eisen”. Justus Liebigs Annalen der Chemie457: 71–82. doi:10.1002/jlac.19274570103.
O. R. Leeuwenkamp; W. P. van Bennekom; E. J. van der Mark; A. Bult (1984). “Nitroprusside, antihypertensive drug and analytical reagent”. Pharmaceutisch Weekblad6 (4): 129–140. doi:10.1007/BF01954040.
Finocchiaro R; D'Eufemia P; Celli M; Zaccagnini M; Viozzi L; Troiani P; Mannarino O; Giardini O. (1998). “Usefulness of cyanide-nitroprusside test in detecting incomplete recessive heterozygotes for cystinuria: a standardized dilution procedure”. Urol Res.26 (6): 401–5. doi:10.1007/s002400050076. PMID9879820.
Carol L. O’Neala, Dennis J. Croucha, Alim A. Fatahb (2000). “Validation of twelve chemical spot tests for the detection of drugs of abuse”. Forensic Science International109 (3): 189–201. doi:10.1016/S0379-0738(99)00235-2. PMID10725655.
Th. Woike; W. Krasser; P. S. Bechthold; S. Haussühl (1984). “Extremely Long-Living Metastable State of Na2[Fe(CN)5NO]·2H2O Single Crystals: Optical”. Phys. Rev. Lett.53: 1767–1770. Bibcode: 1984PhRvL..53.1767W. doi:10.1103/PhysRevLett.53.1767.
Chua SL, Liu Y, Yam JKH, Tolker-Nielsen T, Kjelleberg S, Givskov M, Yang L (2014). “Dispersed cells represent a distinct stage in the transition from bacterial biofilm to planktonic lifestyles”. Nature Communications5. doi:10.1038/ncomms5462.
Jadwiga Tritt-Goc; Narcyz Piślewski; Stanisław K. Hoffmann (1997). “EPR evidence of the paramagnetism of a long-living metastable excited state of a sodium nitroprusside single crystal”. Chemical Physics Letters268 (5–6): 471–474. Bibcode: 1997CPL...268..471T. doi:10.1016/S0009-2614(97)00217-0.
Th. Woike; W. Krasser; P. S. Bechthold; S. Haussühl (1984). “Extremely Long-Living Metastable State of Na2[Fe(CN)5NO]·2H2O Single Crystals: Optical”. Phys. Rev. Lett.53: 1767–1770. Bibcode: 1984PhRvL..53.1767W. doi:10.1103/PhysRevLett.53.1767.
Ikram, H; Low, CJ; Crozier, IG; Shirlaw, T (February 1992). “Hemodynamic effects of nitroprusside on valvular aortic stenosis”. The American Journal of Cardiology69 (4): 361–366. doi:10.1016/0002-9149(92)90234-P. PMID1734649.
Ozsoylu, S; Coşkun, T (January 1984). “Sodium nitroprusside treatment in erythromelalgia”. European Journal of Pediatrics141 (3): 185–187. doi:10.1007/bf00443224. PMID6698066.
Sirinek, KR; Adcock, DK; Levine, BA (January 1989). “Simultaneous infusion of nitroglycerin and nitroprusside to offset adverse effects of vasopressin during portosystemic shunting”. American Journal of Surgery157 (1): 33–37. doi:10.1016/0002-9610(89)90416-9. PMID2491934.
Taradash, MR; Jacobson, LB (September 1975). “Vasodilator therapy of idiopathic lactic acidosis”. The New England Journal of Medicine293 (10): 468–471. doi:10.1056/NEJM197509042931002. PMID239336.
Yusuf, S; Collins, R; MacMahon, S; Peto, R (May 1988). “Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials”. Lancet1 (8594): 1088–92. doi:10.1016/S0140-6736(88)91906-X. PMID2896919.
Blue, MG; Schneider, SM; Noro, S; Fraley, DS (January 1986). “Successful treatment of neuroleptic malignant syndrome with sodium nitroprusside”. Annals of Internal Medicine104 (1): 56–57. doi:10.7326/0003-4819-104-1-56. PMID3940506.
Costard-Jäckle, A; Fowler, MB (January 1992). “Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group”. Journal of the American College of Cardiology19 (1): 48–54. doi:10.1016/0735-1097(92)90050-W. PMID1729345.
Knapp, E; Gmeiner, R (February 1977). “Reduction of pulmonary hypertension by nitroprusside”. International Journal of Clinical Pharmacology and Biopharmacy15 (2): 75–80. PMID885667.
Freitas, AF Jr; Bacal, F; Oliveira Júnior Jde, L; Fiorelli, AI; Santos, RH; Moreira, LF; Silva, CP; Mangini, S; Tsutsui, JM; Bocchi, EA (September 2012). “Sildenafil vs. sodium before nitroprusside for the pulmonary hypertension reversibility test before cardiac transplantation”. Arquivos Brasileiros de Cardiologia99 (3): 848–56. doi:10.1590/S0066-782X2012005000076. PMID22898992.
Palhares, DB; Figueiredo, CS; Moura, AJ (January 1998). “Endotracheal inhalatory sodium nitroprusside in severely hypoxic newborns”. Journal of Perinatal Medicine26 (3): 219–224. doi:10.1515/jpme.1998.26.3.219. PMID9773383.
Benitz, WE; Malachowski, N; Cohen, RS; Stevenson, DK; Ariagno, RL; Sunshine, P (January 1985). “Use of sodium nitroprusside in neonates: efficacy and safety”. The Journal of Pediatrics106 (1): 102–110. doi:10.1016/S0022-3476(85)80477-7. PMID3917495.
Levy, WJ; Bay, JW; Sawhny, B; Tank, T (May 1982). “Aminophylline plus nitroprusside and dopamine for treatment of cerebral vasospasm”. Journal of Neurosurgery56 (5): 646–649. doi:10.3171/jns.1982.56.5.0646. PMID7069476.
Thomas, JE; Rosenwasser, RH (January 1999). “Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: initial observations regarding the use of intraventricular sodium nitroprusside in humans”. Neurosurgery44 (1): 48–57. doi:10.1097/00006123-199901000-00026. PMID9894963.
Dierckx, RA; Peters, O; Ebinger, G; Six, R; Corne, L (February 1986). “Intraarterial sodium nitroprusside infusion in the treatment of severe ergotism”. Clinical Neuropharmacology9 (6): 542–548. doi:10.1097/00002826-198612000-00005. PMID3802106.
Carliner, N; Denune, DP; Finch, CS Jr; Goldberg, LI (January 1974). “Sodium nitroprusside treatment of ergotamine-induced peripheral ischemia”. Journal of the American Medical Association227 (3): 308–309. doi:10.1001/jama.1974.03230160036008. PMID4859658.
Lewis, PJ; Noseworthy, TW; Fitzgerald, AA; Andrews, GC; Geeraert, AJ (February 1986). “Rapid reversal of ergotamine-induced vasospasm”. The Canadian Journal of Neurological Sciences13 (1): 72–74. PMID3955457.
Kunathai, S; Ayuthya, PS (Winter 1989). “Hemodynamic effects of sodium nitroprusside in infants and children with large ventricular septal defect”. Pediatric Cardiology10 (1): 59. doi:10.1007/bf02328639. PMID2704657.
Bernstein, HG; Bogerts, B; Keilhoff, G (Oct 2005). “The many faces of nitric oxide in schizophrenia. A review”. Schizophrenia Research78 (1): 69–86. doi:10.1016/j.schres.2005.05.019. PMID16005189.
Silberberg, G; Ben-Shachar, D; Navon, R (October 2010). “Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder”. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics153B (7): 1318–1328. doi:10.1002/ajmg.b.31112. PMID20645313.
Bernstein, HG; Keilhoff, G; Steiner, J; Dobrowolny, H; Bogerts, B (November 2011). “Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy”. CNS & Neurological Disorders - Drug Targets10 (7): 792–807. doi:10.2174/187152711798072392. PMID21999729.
Yanik, M; Vural, H; Tutkun, H; Zoroğlu, SS; Savaş, HA; Herken, H; Koçyiğit, A; Keleş, H; Akyol, O (February 2004). “The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder”. European Archives of Psychiatry and Clinical Neuroscience254 (1): 43–47. doi:10.1007/s00406-004-0453-x. PMID14991378.
Fontoura, PC; Pinto, VL; Matsuura, C; Resende Ade, C; de Bem, GF; Ferraz, MR; Cheniaux, E; Brunini, TM; Mendes-Ribeiro, AC (October 2012). “Defective Nitric Oxide–Cyclic Guanosine Monophosphate Signaling in Patients With Bipolar Disorder: A Potential Role for Platelet Dysfunction”. Psychosomatic Medicine74 (8): 873–877. doi:10.1097/PSY.0b013e3182689460. PMID23023680.
Bielau, H; Brisch, R; Bernard-Mittelstaedt, J; Dobrowolny, H; Gos, T; Baumann, B; Mawrin, C; Bernstein, HG; Bogerts, B; Steiner, J (June 2012). “Immunohistochemical evidence for impaired nitric oxide signaling of the locus coeruleus in bipolar disorder”. Brain Research1459: 91–99. doi:10.1016/j.brainres.2012.04.022. PMID22560594.
Gałecki, P; Maes, M; Florkowski, A; Lewiński, A; Gałecka, E; Bieńkiewicz, M; Szemraj, J (March 2011). “Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder”. Journal of Affective Disorders129 (1-3): 175–82. doi:10.1016/j.jad.2010.09.005. PMID20888049.
Finocchiaro R; D'Eufemia P; Celli M; Zaccagnini M; Viozzi L; Troiani P; Mannarino O; Giardini O. (1998). “Usefulness of cyanide-nitroprusside test in detecting incomplete recessive heterozygotes for cystinuria: a standardized dilution procedure”. Urol Res.26 (6): 401–5. doi:10.1007/s002400050076. PMID9879820.
Carol L. O’Neala, Dennis J. Croucha, Alim A. Fatahb (2000). “Validation of twelve chemical spot tests for the detection of drugs of abuse”. Forensic Science International109 (3): 189–201. doi:10.1016/S0379-0738(99)00235-2. PMID10725655.